IceCure Medical Shares Jump After Update on Commercial Adoption of Breast Cancer Cryoablation Procedures

MT Newswires Live

06/18

IceCure Medical (ICCM) shares rose over 230% on Wednesday after the company provided an update on commercial adoption of its ProSense procedures for breast cancer cryoablation following US Food and Drug Administration marketing authorization in October 2025.

The company said US active commercial install base of its ProSense systems has grown 70%, reflecting accelerating physician adoption across major markets including New York, Los Angeles, Dallas and Atlanta.

Separately, IceCure said it has agreed to sell shares and warrants to a single healthcare-focused institutional investor in a private placement expected to raise approximately $5.5 million in gross proceeds.

The deal is expected to close on or about Thursday, with proceeds earmarked for working capital and general corporate purposes, the company added.

Price: 7.95, Change: +5.82, Percent Change: +273.24

免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。

热议股票

{"basename":"/hans","ssrTDKData":{"titleTemplate":"%s - 老虎证券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎证券,老虎证券开户,老虎券商,老虎证券官网,老虎证券app,tigertrade老虎证券,股票,炒股,新加坡股票交易平台,投资,投资理财","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.itiger.com/hans/news/2644723293"},"companyName":"老虎证券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2644723293\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2644723293?lang=zh_CN&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-06-18 02:09","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2644723293","market":"sg","top_or_hot":-1,"title":"IceCure Medical Shares Jump After Update on Commercial Adoption of Breast Cancer Cryoablation Procedures","media":"MT Newswires Live","content":"<html><body><p> IceCure Medical (ICCM) shares rose over 230% on Wednesday after the company provided an update on commercial adoption of its ProSense procedures for breast cancer cryoablation following US Food and Drug Administration marketing authorization in October 2025.</p><p>The company said US active commercial install base of its ProSense systems has grown 70%, reflecting accelerating physician adoption across major markets including New York, Los Angeles, Dallas and Atlanta.</p><p>Separately, IceCure said it has agreed to sell shares and warrants to a single healthcare-focused institutional investor in a private placement expected to raise approximately $5.5 million in gross proceeds.</p><p>The deal is expected to close on or about Thursday, with proceeds earmarked for working capital and general corporate purposes, the company added.</p><p>Price: 7.95, Change: +5.82, Percent Change: +273.24</p></body></html>","source":"mtnewswires_news","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>IceCure Medical Shares Jump After Update on Commercial Adoption of Breast Cancer Cryoablation Procedures</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nIceCure Medical Shares Jump After Update on Commercial Adoption of Breast Cancer Cryoablation Procedures\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1092851196\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">MT Newswires Live </p>\n<p class=\"h-time\">2026-06-18 02:09</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html><body><p> IceCure Medical (ICCM) shares rose over 230% on Wednesday after the company provided an update on commercial adoption of its ProSense procedures for breast cancer cryoablation following US Food and Drug Administration marketing authorization in October 2025.</p><p>The company said US active commercial install base of its ProSense systems has grown 70%, reflecting accelerating physician adoption across major markets including New York, Los Angeles, Dallas and Atlanta.</p><p>Separately, IceCure said it has agreed to sell shares and warrants to a single healthcare-focused institutional investor in a private placement expected to raise approximately $5.5 million in gross proceeds.</p><p>The deal is expected to close on or about Thursday, with proceeds earmarked for working capital and general corporate purposes, the company added.</p><p>Price: 7.95, Change: +5.82, Percent Change: +273.24</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4082","symbol_name":"医疗保健设备","start_time":0,"source_url":"https://www.mtnewswires.com/","article_id":"2644723293","we_media_id":"1092851196","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2644723293","pubTimestamp":1781719747,"columns":[],"sourceInfo":{"source_id":"mtnewswires_news","name":"MT Newswires"},"weMediaInfo":{"media_name":"MT Newswires Live","introduction":"The most recognized names in North America, Europe and Asia rely on MT Newswires to power their applications. Better news, better service, better price.","home_visible":1,"id":"1092851196","head_image":"https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e"},"summary":"IceCure Medical  shares rose over 230% on Wednesday after the company provided an update on commercial adoption of its ProSense procedures for breast cancer cryoablation following US Food and Drug Administration marketing authorization in October 2025.The company said US active commercial install base of its ProSense systems has grown 70%, reflecting accelerating physician adoption across major markets including New York, Los Angeles, Dallas and Atlanta.Separately, IceCure said it has agreed to sell shares and warrants to a single healthcare-focused institutional investor in a private placement expected to raise approximately $5.5 million in gross proceeds.The deal is expected to close on or about Thursday, with proceeds earmarked for working capital and general corporate purposes, the company added.Price: 7.95, Change: +5.82, Percent Change: +273.24","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4082":"医疗保健设备","ICCM":"IceCure Medical Ltd."},"translate_title":"乳腺癌冷冻消融手术商业采用的最新消息后，IceCure Medical股价上涨","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"ICCM":1.5},"content_text":"IceCure Medical (ICCM) shares rose over 230% on Wednesday after the company provided an update on commercial adoption of its ProSense procedures for breast cancer cryoablation following US Food and Drug Administration marketing authorization in October 2025.The company said US active commercial install base of its ProSense systems has grown 70%, reflecting accelerating physician adoption across major markets including New York, Los Angeles, Dallas and Atlanta.Separately, IceCure said it has agreed to sell shares and warrants to a single healthcare-focused institutional investor in a private placement expected to raise approximately $5.5 million in gross proceeds.The deal is expected to close on or about Thursday, with proceeds earmarked for working capital and general corporate purposes, the company added.Price: 7.95, Change: +5.82, Percent Change: +273.24","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":true,"editions":null,"column":"","sentiment":"1","news_tag":"corporation","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"}}}